Activating mutations of Ras protein are found in ~30% of all human tumours.21 Even in cancers where an activating mutation of Ras protein is absent, the upstream or downstream signalling components of the Ras/MEK pathway are often inappropriately activated. Here, MAP2K7 is linked to neoplasm.